1. A method of reducing inter-patient variability in a drug treatment, comprising;
i. identifying inter-patient variability in said drug treatment;
ii. preparing a deuterated analog of said drug; and
iii. using said deuterated analog in said drug treatment to reduce inter-patient variability of said drug treatment.
2. The method as recited in claim 1 wherein said deuterated analog has deuteration at one or more sites metabolized by a cytochrome P450.
3. The method as recited in claim 2 wherein said cytochrome P450 is a polymorphically expressed cytochrome P450.
4. The method as recited in claim 3 wherein said polymorphically expressed cytochrome P450 is selected from the group consisting of CYP3A4, CYP2D6 and CYP2C19.
5. The method as recited in claim 1 wherein said interpatient variability is in the frequency or severity of side effects experienced.
6. The method as recited in claim 1 wherein said interpatient variability is in the half-life (t12) of a drug in the plasma.
7. The method as recited in claim 1 wherein said interpatient variability is in the maximum plasma concentration (Cmax) of a drug in the plasma.
8. The method as recited in claim 1 wherein said interpatient variability is in the time at maximal plasma concentration (Tmax) of a drug in the plasma.
9. The method as recited in claim 1 wherein said interpatient variability is in the area under the time-versus-concentration curve (AUC) of a drug in the plasma.
10. The method as recited in claim 1 wherein said interpatient variability is in the metabolite profile of the drug.
11. The method as recited in claim 1 wherein said drug is venlafaxine.
12. The method as recited in claim 11 wherein using said deuterated analog yields a reduced inter-patient variability in plasma half life (t12) of 20% or more compared to non-deuterated venlafaxine.
13. The method as recited in claim 11 wherein using said deuterated analog yields a reduced inter-patient variability in maximum plasma concentration (Cmax) of 30% or more compared to non-deuterated venlafaxine.
14. The method as recited in claim 11 wherein using said deuterated analog yields a reduced inter-patient variability in time at maximal plasma concentration (Tmax) of 15% or more compared to non-deuterated venlafaxine.
15. The method as recited in claim 11 wherein using said deuterated analog yields a reduced inter-patient variability in plasma area under the time-versus-concentration curve (AUC) of 20% or more compared to non-deuterated venlafaxine.
16. The method as recited in claim 11 wherein using said deuterated analog yields a reduction in the incendence of one or more side effects.
17. The method as recited in claim 16 wherein using said deuterated analog yields at least 25% fewer side effects overall than non-deuterated venlafaxine.
18. The method as recited in claim 16 wherein the side effect is selected from the group consisting of drowsiness, dry mouth, fatigue or somnolence, headache, lightheadedness, nausea, emesis, mydriasis, anxiety, nervousness, and insomnia, dizziness, anxiety, asthenia, sweating, anorexia, weight gain, activation of maniahypomania, and suicidal ideation.
19. A method of reducing interpatient variability in a population of patients taking a drug comprising
i. identifying a population of patients having interpatient variability; and
ii. administering to a population of patients a deuterated analog of a drug.
20. A deuterated analog of venlafaxine having a reduced inter-patient variability in plasma half life of 20% or more compared to non-deuterated venlafaxine.
21. A deuterated analog of venlafaxine having a reduced inter-patient variability in maximum plasma concentration in humans of 30% or more compared to non-deuterated venlafaxine.
22. A deuterated analog of venlafaxine having a reduced inter-patient variability in maximum plasma concentration in humans of 40% or more compared to non-deuterated venlafaxine.
23. A deuterated analog of venlafaxine having a reduced inter-patient variability time at maximal plasma concentration in humans of 15% or more compared to non-deuterated venlafaxine.
24. A deuterated analog of venlafaxine having a reduced inter-patient variability in plasma area under the time-versus-concentration curve 20% or more compared to non-deuterated venlafaxine.
25. A deuterated analog of venlafaxine which causes at least 25% fewer side effects than non-deuterated venlafaxine.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A seed of corn variety CV715590, wherein a sample of seed of corn variety CV715590 has been deposited under ATCC Accession No. PTA-10348.
2. A plant of corn variety CV715590, wherein a sample of seed of corn variety CV715590 has been deposited under ATCC Accession No. PTA-10348.
3. A plant part of the plant of claim 2.
4. The plant part of claim 3, further defined as pollen, an ovule or a cell.
5. A tissue culture of regenerable cells of the plant of claim 2.
6. The tissue culture of claim 5, wherein the regenerable cells are from embryos, meristematic cells, pollen, leaves, roots, root tips, anther, pistil, flower, seed, or stem.
7. A corn plant regenerated from the tissue culture of claim 5, wherein the regenerated corn plant expresses all of the physiological and morphological characteristics of the corn variety CV715590, wherein a sample of seed of corn variety CV715590 has been deposited under ATCC Accession No. 10348.
8. A method of producing corn seed, comprising crossing the plant of claim 2 with itself or a second corn plant.
9. An F1 hybrid seed produced by crossing the plant of claim 2 with a second, distinct corn plant.
10. An F1 hybrid plant grown from the seed of claim 9.
11. A method of producing a plant of corn variety CV715590 comprising an added desired trait, the method comprising introducing a transgene conferring the desired trait into a plant of corn variety CV715590, wherein a sample of seed of corn variety CV715590 has been deposited under ATCC Accession No. PTA-10348.
12. The method of claim 11, wherein the desired trait is selected from the group consisting of male sterility, herbicide tolerance, insect or pest resistance, disease resistance, modified fatty acid metabolism, and modified carbohydrate metabolism.
13. The method of claim 12, wherein the desired trait is herbicide tolerance and the tolerance is conferred to an herbicide selected from the group consisting of glyphosate, sulfonylurea, imidazalinone, dicamba, glufosinate, phenoxy proprionic acid, cycloshexone, triazine, benzonitrile and broxynil.
14. The method of claim 11, wherein the desired trait is insect resistance and the transgene encodes a Bacillus thuringiensis (Bt) endotoxin.
15. A plant produced by the method of claim 11, wherein the plant comprises the desired trait and otherwise comprises all of the physiological and morphological characteristics of corn variety CV715590 when grown in the same environmental conditions, wherein a sample of seed of corn variety CV715590 has been deposited under ATCC Accession No. PTA-10348.
16. A method of introducing a single locus conversion into corn variety CV715590 comprising:
(a) crossing a plant of variety CV715590 with a second plant comprising a desired single locus to produce F1 progeny plants, wherein a sample of seed of corn variety CV715590 has been deposited under ATCC Accession No. PTA-10348;
(b) selecting F1 progeny plants that have the single locus to produce selected F1 progeny plants;
(c) crossing the selected progeny plants with at least a first plant of variety CV715590 to produce backcross progeny plants;
(d) selecting backcross progeny plants that have the single locus and physiological and morphological characteristics of corn variety CV715590 to produce selected backcross progeny plants; and
(e) repeating steps (c) and (d) one or more times in succession to produce selected second or higher backcross progeny plants that comprise the single locus and otherwise comprise all of the physiological and morphological characteristics of corn variety CV715590 when grown in the same environmental conditions.
17. The method of claim 16, wherein the single locus confers a trait selected from the group consisting of male sterility; herbicide tolerance; insect or pest resistance; disease resistance; modified fatty acid metabolism; and modified carbohydrate metabolism.
18. The method of claim 17, wherein the trait is tolerance to an herbicide selected from the group consisting of glyphosate, sulfonylurea, imidazalinone, dicamba, glufosinate, phenoxy proprionic acid, cycloshexone, triazine, benzonitrile and broxynil.
19. The method of claim 17, wherein the trait is insect resistance and the insect resistance is conferred by a transgene encoding a Bacillus thuringiensis endotoxin.
20. A plant of corn variety CV715590, further defined as comprising a single locus conversion, wherein the single locus conversion was introduced into said corn variety CV715590 by backcrossing or genetic transformation, wherein a sample of seed of corn variety CV715590 has been deposited under ATCC Accession No. PTA-10348.
21. A method of producing a seed of a corn plant derived from the corn variety CV715590, the method comprising the steps of:
(a) preparing a progeny plant derived from corn variety CV715590 by crossing a plant of the corn variety CV715590 with a corn plant of a second variety, wherein a sample of seed of corn variety CV715590 has been deposited under ATCC Accession No. PTA-10348; and
(b) crossing the progeny plant with itself or a second plant to produce a seed of a progeny plant of a subsequent generation.
22. A method of producing a commodity plant product comprising obtaining the plant of claim 10 or a part thereof and producing said commodity plant product therefrom.
23. The method of claim 22, wherein the commodity plant product is starch, seed oil, corn syrup or protein.